Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- USD | -.--% | -.--% | -.--% |
Apr. 26 | Shanghai Henlius Biotech's Cancer Drug Gets the Nod from US FDA | MT |
Apr. 24 | Shanghai Henlius Biotech Doses 1st Patient in Fibrosis Drug Clinical Study in China | MT |
Sales 2024 * | 5.89B 815M | Sales 2025 * | 6.46B 893M | Capitalization | 8.44B 1.17B |
---|---|---|---|---|---|
Net income 2024 * | 600M 82.97M | Net income 2025 * | 713M 98.6M | EV / Sales 2024 * | 1.43 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.31 x |
P/E ratio 2024 * |
13.9
x | P/E ratio 2025 * |
11.7
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 15.03% |
Managers | Title | Age | Since |
---|---|---|---|
Wei Dong Jiang
FOU | Founder | - | 09-11-30 |
Jun Zhu
CEO | Chief Executive Officer | 46 | 21-11-29 |
Wei Huang
PSD | President | 56 | 20-09-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Qi Yu Chen
BRD | Director/Board Member | 52 | 13-01-14 |
Tak Young So
BRD | Director/Board Member | 54 | 19-09-01 |
Xiao Hui Guan
BRD | Director/Board Member | 53 | 18-12-23 |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-4.06% | 86.13B | |
+1.97% | 39.82B | |
+56.59% | 25.23B | |
-14.82% | 15.36B | |
-8.82% | 11.95B | |
-16.29% | 11.6B | |
-41.58% | 11.51B | |
+6.14% | 8.71B | |
-7.02% | 8.12B |
- Stock Market
- Equities
- 2696 Stock
- SGBCF Stock